Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patients had stage III/IV (or stage II with bulky disease...

Полное описание

Библиографические подробности

Главные авторы:	Michael Herold, Eva Hoster, Ann Janssens, Helen McCarthy, Alessandra Tedeschi, Chris Pocock, Andras Rosta, Marek Trněný, Tina G. Nielsen, Andrea Knapp, Wolfgang Hiddemann, Robert Marcus
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2022-03-01
Серии:	HemaSphere
Online-ссылка:	http://journals.lww.com/10.1097/HS9.0000000000000699
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!